- Diagnos Inc. (ADK) extends its contract with Novo Nordisk for the follow-up of diabetic patients under treatment
- Diagnos detects critical health problems using its FLAIRE artificial intelligence platform
- FLAIRE helps supports the patients by measuring positive effects during treatment
- Patients will be monitored for a six month period with two screenings
- Diagnos Inc. (ADK) is down 2.50 per cent trading at $0.19 per share as of 11:54 a.m. ET
Diagnos (ADK) has extended its contract with Novo Nordisk for the follow-up of diabetic patients under treatment with drugs from Novo’s therapeutic portfolio.
Diagnos is a Canadian corporation dedicated to early detection of critical health problems based on its FLAIRE artificial intelligence platform. FLAIRE allows for quick modifying and developing of applications.
André Larente, CEO of DIAGNOS, commented,
“Our highly innovative artificial intelligence and expertise in non-invasive eye screening will support the specialists in monitoring diabetic patients under treatment with Novo Nordisk’s drugs through the analysis of the patients’ retina to measure the positive effects their treatment has on them, not only for diabetes but also for hypertension, leading us towards the future establishment of measures to reduce the risk of major cardiovascular diseases by using Diagnos’ technology.”
Dr. Hadi Chakor, Chief Medical Officer at Diagnos, stated,
“Our method carries the potential for early detection and prevent the vision loss from diabetic complications… Also, by using the same retina photograph that we use for retinopathy screening this allows us to detect the early anomalies of retinal micro vascularization and to provide a cardiovascular risk score to decrease morbidity and mortality in the population at risk.”
Over a six month period, Diagnos will monitor the evolution of diseases in 500 patients using its non-invasive technology. One screening will occur at the beginning of the program and a second screening will happen six months later.
Novo Nordisk is a global healthcare company with a therapeutic portfolio that reduces the risk of developing retinopathy and of suffering from major cardiovascular events such as heart attack, stroke, or even death in adults with type two diabetes mellitus.
Diagnos Inc. (ADK) is down 2.50 per cent trading at $0.19 per share as of 11:54 a.m. ET.
